Targeted Drug Delivery Research Business Report 2025: Global Market to Reach $24.9 Billion by 2030 - Smart Polymers and External Stimuli Open New Frontiers in Precision Delivery - ResearchAndMarkets.com

The "Targeted Drug Delivery - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

The global market for Targeted Drug Delivery was valued at US$10.0 Billion in 2024 and is projected to reach US$24.9 Billion by 2030, growing at a CAGR of 16.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Targeted drug delivery systems are revolutionizing the way therapeutic agents are administered by directing drugs specifically to diseased tissues or cells, thereby minimizing systemic exposure and associated side effects. Unlike conventional systemic therapies, which often impact healthy tissues, targeted approaches improve drug concentration at the site of action, enhance therapeutic efficacy, and reduce off-target toxicity. This shift is particularly crucial in oncology, neurology, and immunology, where treatment specificity can significantly influence patient outcomes.

What Are the Factors Driving Growth in the Targeted Drug Delivery Market?

The targeted drug delivery market is growing rapidly as pharmaceutical innovation pivots toward precision medicine, and as healthcare systems seek therapies that maximize efficacy while minimizing systemic burden. Advances in nanocarrier engineering, biomolecular targeting, and drug conjugation technologies are expanding therapeutic potential across multiple disease categories. Simultaneously, the promise of personalized, tissue-specific treatments is aligning with regulatory incentives, academic research, and commercial partnerships.

Looking ahead, market momentum will depend on how effectively developers can integrate delivery innovations with therapeutic pipelines, meet evolving regulatory standards, and demonstrate clinical and economic value. As treatment paradigms shift toward more individualized, mechanism-based interventions, targeted drug delivery is poised to become a foundational enabler of next-generation medicine - driving growth at the nexus of technology, biology, and patient-centered care.

How Are Nanotechnology, Biomaterials, and Smart Carriers Enhancing Targeted Drug Delivery Platforms?

Advancements in nanotechnology and biomaterials are enabling the development of highly engineered carriers - such as liposomes, dendrimers, polymeric nanoparticles, and antibody-drug conjugates - that improve drug stability, control release kinetics, and facilitate selective targeting. These systems can be surface-functionalized with ligands, antibodies, or peptides to bind specifically to receptors expressed on diseased cells, enabling receptor-mediated uptake and intracellular delivery of payloads with high precision.

Smart delivery systems are also being developed to respond to physiological stimuli - such as pH, enzymes, or temperature - ensuring drug activation only under specific conditions within diseased tissue. Such stimulus-responsive platforms enhance drug control, reduce premature degradation, and support localized therapeutic actions. Emerging innovations, including exosome-based delivery and CRISPR-loaded nanoparticles, are pushing the frontiers of targeted delivery by combining biological compatibility with molecular-level control, opening new pathways for treating previously inaccessible conditions.

Which Therapeutic Areas and Delivery Routes Are Driving Demand for Targeted Drug Delivery Solutions?

Oncology remains the largest application area for targeted drug delivery due to the need for site-specific chemotherapy, immunotherapy, and radiopharmaceuticals. Technologies such as antibody-drug conjugates and nanoparticle-based formulations are enabling selective tumor targeting, improving treatment response rates and reducing systemic side effects. Similarly, targeted delivery is gaining traction in central nervous system (CNS) disorders, where crossing the blood-brain barrier remains a significant challenge for conventional drugs.

Beyond oncology and neurology, autoimmune diseases, infectious diseases, and rare genetic disorders are emerging as high-growth segments. Intravenous administration remains dominant for systemic targeting, but oral, intranasal, transdermal, and implantable routes are being developed for localized or sustained release applications. The expansion of delivery modalities tailored to disease-specific needs is increasing the versatility of targeted systems, making them viable across a broader spectrum of indications and patient populations.

How Are Regulatory Pathways, Market Access, and Clinical Translation Influencing Commercialization?

Targeted drug delivery products must navigate complex regulatory pathways due to their novel mechanisms, composite structures, and potential safety concerns. Agencies such as the FDA and EMA are refining guidance for nanomedicine and combination products, focusing on aspects like pharmacokinetics, toxicity profiling, and product characterization. Early engagement with regulators, robust clinical evidence, and quality-by-design (QbD) approaches are becoming critical for accelerating approval and ensuring reproducibility at scale.

Market access is equally dependent on cost-effectiveness, manufacturing scalability, and clinical adoption. While targeted therapies often carry high development costs, their ability to improve outcomes and reduce downstream treatment burdens can support favorable health economics. Collaborations between drug developers, device companies, and delivery technology providers are becoming more common to bridge scientific innovation and commercial viability. As real-world data and personalized diagnostics expand, payer and clinician acceptance of targeted drug delivery solutions is gaining traction across global healthcare markets.

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as AbbVie Inc., Amgen Inc., AstraZeneca PLC, Becton Dickinson and Company, Bristol-Myers Squibb and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Cardiovascular Diseases segment, which is expected to reach US$8.6 Billion by 2030 with a CAGR of a 14.5%. The Pulmonary Diseases segment is also set to grow at 16.9% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $2.6 Billion in 2024, and China, forecasted to grow at an impressive 15.6% CAGR to reach $3.9 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Segments

• Disease Type (Cardiovascular Diseases, Pulmonary Diseases, Infectious Diseases, Endocrine Diseases, Oncological Disorders)
• Application (First Order Targeting, Second Order Targeting, Third Order Targeting)
• End-User (Hospitals, Clinics, Other End-Users)

Tariff Impact Analysis: Key Insights for 2025

What's Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry

Key Attributes:

Key Topics Covered:

MARKET OVERVIEW

• Influencer Market Insights
• World Market Trajectories
• Targeted Drug Delivery - Global Key Competitors Percentage Market Share in 2025 (E)
• Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)

MARKET TRENDS & DRIVERS

• Precision Medicine and Oncology Drive Rapid Innovation in Targeted Drug Delivery Technologies
• Nanocarriers, Liposomes, and Antibody-Drug Conjugates Enable Site-Specific Therapeutic Delivery
• Regulatory Approvals of mRNA and Lipid Nanoparticle Platforms Accelerate Adoption in Non-Viral Modalities
• Reduced Off-Target Effects and Enhanced Bioavailability Strengthen Use in Rare and Chronic Conditions
• Integration of Imaging-Guided and pH-Sensitive Delivery Systems Enhances Tumor Selectivity
• Biotech Startups Focus on Ligand-Targeted and Receptor-Specific Drug Delivery Innovations
• Inhalable, Transdermal, and Injectable Formats Expand Application in Pain, CNS, and Autoimmune Disorders
• Controlled Release Technologies Improve Dosing Compliance and Patient Outcomes
• R&D in RNA, CRISPR, and Gene Therapy Expands Scope for Targeted Nucleic Acid Delivery
• Smart Polymers and External Stimuli (e.g., magnetic, ultrasonic) Open New Frontiers in Precision Delivery

FOCUS ON SELECT PLAYERS: Some of the 32 companies featured in this report

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca PLC
• Becton Dickinson and Company
• Bristol-Myers Squibb
• Camurus AB
• Confo Therapeutics
• Daiichi Sankyo Co., Ltd.
• Eli Lilly and Company
• Evox Therapeutics Ltd
• Genmab A/S
• GlaxoSmithKline plc
• ImmunoGen, Inc.
• Ionis Pharmaceuticals, Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Precision NanoSystems Inc.
• Seagen Inc.

For more information about this report visit https://www.researchandmarkets.com/r/z38q1e

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250529615982/en/